Lumida
/FLGT
⌘K
Fulgent Genetics Inc

Fulgent Genetics Inc

FLGT
$20.16USD↓-1.90%-0.39 today

MARKET CAP

572.6M

P/E (TTM)

2,016.0x

FWD P/E

—

DAY RANGE

$20 – $21

52W RANGE

$13
$31

AI Summary

Stalk
Buy NowMedium

FLGT remains in a Stage 2 advancing phase with a bullish medium-term bias supported by the active Lockout Rally continuation pattern. Price is currently in a corrective pullback into the 9/21 EMA zone above the rising 50-day MA, offering a disciplined entry point. No short-term exhaustion or overbought stress is visible in the neutral OB/OS context. The speculative strategy demands high selectivity, justifying a Buy Now on shallow pullback acceptance in the EMA zone.

  • ↑Precision diagnostics segment up 17.8% YoY, adding $6.7M revenue
  • ↑Bako & StrataDX deals to contribute ~$50–55M top-line in 2026
  • ↓Loss of largest customer will reduce revenue by ~$59M in 2026
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Fulgent Genetics, Inc. (NASDAQ: FLGT) is a biotechnology company specializing in genetic testing services and precision diagnostics. The company is primarily positioned in the laboratory services and therapeutic development sectors, aiming to leverage advancements in AI and digital pathology to expand its market reach. With a focus on non-invasive and efficient genetic testing solutions, Fulgent operates in a competitive landscape while addressing significant unmet medical needs in areas such as oncology and reproductive health.

Bull says

  • ↑Precision diagnostics segment up 17.8% YoY, adding $6.7M revenue
  • ↑Bako & StrataDX deals to contribute ~$50–55M top-line in 2026
  • ↑Investing in AI/digital pathology to improve turnaround and accuracy
  • ↑Projected cash of ~$636M by YE 2026 underpins growth plans
  • ↑Rising demand for precision medicine supports long-term test uptake
  • ↑High book-to-price ratio and positive analyst revisions suggest undervaluation

Bear says

  • ↓Loss of largest customer will reduce revenue by ~$59M in 2026
  • ↓Gross margins expected to drop ~4pp in Q1 with further Q2 pressure
  • ↓Negative earnings yield undermines investor appeal
  • ↓Integration of Bako/StrataDX carries execution and synergy risks
  • ↓Operating expenses rose to $56.1M in Q1 amid falling revenue
  • ↓Weak growth and profitability factor scores highlight value-trap risk

Investment themes with FLGT

Health Care Providers↓ -0.61%

UNH · CVS · HCA

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-02-2026neutral

Transcript signals

Bull points

  • We were excited to announce during the first quarter that we completed the acquisition of Bako Diagnostics and Strata DX. This acquisition adds to our market presence in anatomic pathology and more than doubles the size of our pathology sales teams.
  • We believe a well-trained, cross-functional sales team will pay dividends as we look to expand our market size in anatomic pathology.
  • We are excited to announce that during the quarter, we received MoldDX approval and pricing for our PGX test.

Bear points

  • We ended the first quarter at $71.1 million, which was a decrease of 3.2% year-over-year and 14.6% quarter-over-quarter, driven by the reduction in sales to our large customer who has begun transitioning testing in-house
  • precision diagnostics revenue for the first quarter was $40.2 million, a decrease of 8.8% year-over-year and down 16.5% sequentially.
  • Anatomic pathology revenue for the first quarter was $25.1 million, a decrease of 0.9% year-over-year and down 7.2% sequentially.
Read full transcript analysis ›